Table 1.
The information of included patients with APT-SICH.
| Characteristics | PR n = 40 | NPR n = 157 | P value |
|---|---|---|---|
| Male -no. (%) | 31 (77.5%) | 116 (73.9%) | 0.640 |
| Age -median (IQR)-years | 63 (51–72) | 56 (48–66) | 0.155 |
| Comorbidities | |||
| Dyslipidemia -no. (%) | 3 (7.5%) | 14 (8.9%) | 0.776 |
| Diabetes mellitus -no. (%) | 12 (30.0%) | 42 (26.8%) | 0.682 |
| Coronary heart disease -no. (%) | 12 (30.0%) | 46 (29.3%) | 0.931 |
| Ischemic stroke -no. (%) | 17 (42.5%) | 43 (27.4%) | 0.064 |
| Intracerebral hemorrhage history -no. (%) | 11 (27.5%) | 15 (9.6%) | 0.003+ |
| Current smoker -no. (%) | 18 (45.0%) | 48 (30.6%) | 0.085 |
| Regular alcohol abuse -no. (%) | 4 (10.0%) | 18 (11.5%) | 0.793 |
| Antiplatelet therapy prehemorrhage -no. (%) | <0.001+ | ||
| Aspirin | 17 (42.5%) | 111 (70.7%) | |
| Clopidogrel | 2 (5.0%) | 13 (8.3%) | |
| DAPT | 21 (52.5%) | 33 (21.0%) | |
| Clinical/CT findings on admission | |||
| Left side -no. (%) | 14 (35.0%) | 51 (32.5%) | 0.345 |
| Hemorrhage location -no. (%) | 0.181 | ||
| Supratentorial deep | 19 (47.5%) | 102 (65.0%) | |
| Supratentorial lobar | 19 (47.5%) | 33 (21.0%) | |
| Cerebella | 2 (5.0%) | 22 (14.0%) | |
| Bleeding to ventricle -no. (%) | 23 (57.5%) | 107 (68.2%) | 0.205 |
| Hematoma volume -median (IQR)-cc | 85.9 (81.4–95.0) | 44.8 (33.2–69.7) | <0.001+ |
| Preoperative hematoma extension -no. (%) | 10 (25.0%) | 41(26.1%) | 0.886 |
| Neurological statues on admission | |||
| mRS -median (IQR) | 4 (4–5) | 4 (4–5) | 0.379 |
| GCS -median (IQR) | 5.5 (3–9) | 6 (3–9) | 0.659 |
| ICH score -median (IQR) | 3 (3–4) | 3 (2–3) | 0.088 |
| Surgery-no. (%) | 0.084 | ||
| Craniectomy | 27 (67.5%) | 90 (57.3%) | |
| Endoscopic surgery | 5 (12.5%) | 19 (12.1%) | |
| Minimally invasive surgery† | 8 (20.0%) | 48 (30.6%) | |
| Time from hemorrhage to surgery -median (IQR)-hours | 18.3 (13.4–32.2) | 25.6 (15.0–36.5) | 0.077 |
| Preoperative laboratory examination | |||
| Platelet count -median (IQR)- × 109 | 216.0 (199.5–226.8) | 216.3 (206.0–238.7) | 0.338 |
| APTT -median (IQR)-s | 24.8 (22.4–28.0) | 24.6 (24.5–30.4) | 0.078 |
| PT -median (IQR)-s | 12.6 (12.0–13.1) | 13.4 (12.3–13.1) | 0.264 |
| Fbg -median (IQR)-g/l | 2.6 (2.2–3.1) | 2.8 (2.4–3.6) | 0.004+ |
| CK-MA -no. (%) | <0.001+ | ||
| >70 mm | 11 (27.5%) | 7 (4.5%) | |
| 50~70 mm | 28 (70.0%) | 136 (86.6%) | |
| <50 mm | 1 (2.5%) | 14 (8.9%) | |
| Novel coagulation classification | <0.001+ | ||
| I | 11 (27.5%) | 17 (10.8%) | |
| IIa | 10 (25.0%) | 22 (14.0%) | |
| IIb | 18 (45.0%) | 104 (66.3%) | |
| III | 1 (2.5%) | 14 (8.9%) |
+
The parameter is statistically significant.
†
Minimally invasive surgery included the only minimally invasive surgery and minimally invasive surgery + fibrinolytic therapy.
APT-SICH, severe spontaneous intracerebral hemorrhage patients on antiplatelet therapy; PR, postoperative rebleeding; NPR, no postoperative rebleeding; DAPT, dual antiplatelet therapy; mRS, modified Rankin scale; GCS, Glasgow Coma Score; APTT, activated partial thromboplastin time; PT, prothrombin time; Fbg, fibrinogen.